avarol has been researched along with Psoriasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amigó, M; De Rosa, S; Lamme, E; Olthuis, D; Payá, M; Schalkwijk, J; Terencio, MC | 1 |
| Amigó, M; Braza-Boïls, A; De Rosa, S; Payá, M; Terencio, MC | 1 |
2 other study(ies) available for avarol and Psoriasis
| Article | Year |
|---|---|
Identification of avarol derivatives as potential antipsoriatic drugs using an in vitro model for keratinocyte growth and differentiation.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Drug Evaluation, Preclinical; Dysidea; Elafin; Enzyme-Linked Immunosorbent Assay; Humans; In Vitro Techniques; Interleukin-8; Keratinocytes; Keratins; Membrane Proteins; Psoriasis; RNA, Messenger; Sesquiterpenes; Tumor Necrosis Factor-alpha | 2006 |
Avarol inhibits TNF-alpha generation and NF-kappaB activation in human cells and in animal models.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermis; Female; Humans; Hyperplasia; Inflammation; Inflammation Mediators; Keratinocytes; Mice; Monocytes; NF-kappa B p50 Subunit; Peroxidase; Psoriasis; Sesquiterpenes; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha | 2008 |